Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Meyer Michel Samama is active.

Publication


Featured researches published by Meyer Michel Samama.


Thrombosis Research | 2010

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults☆

Meyer Michel Samama; Satoshi Kunitada; Andŗe Oursin; François Depasse; S. Heptinstall

INTRODUCTION Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response to edoxaban, ximelagatran, and dalteparin in healthy, elderly adults. MATERIALS AND METHODS In this open-label, active-controlled clinical trial, 40 adults (65-75 years), were randomised to: oral edoxaban (60 mg, twice-daily, 7 doses), subcutaneous dalteparin (5000 IU, once-daily, 4 doses), oral ximelagatran (24 mg, twice-daily, 7 doses) or no drug. Blood samples were taken before, and 1.5, 4, 12, 24, 72, 84, 96, 108, 120, and 144 hours after, the first dose. The primary outcomes were changes in thrombin-antithrombin complex, prothrombin fragment 1+2 and D-dimer, and adverse events. Additional biomarkers of coagulation, and endothelial cell and platelet activation were compared (ANOVA). RESULTS All subjects completed the study. Inhibition of thrombin generation lag time, peak, and constant velocity index were significantly greater, and extended for a longer period of time, following edoxaban administration, compared with dalteparin. We found that the traditional assay for anti-FXa activity was not appropriate for the new anticoagulants. Biomarker changes following edoxaban administration (including prolongation of prothrombin time) reflected inhibition of Factor Xa; there was no effect on platelet, tissue factor or endothelial activation. There were no clinically significant changes in primary outcomes. No serious adverse events were reported. CONCLUSION Oral administration of edoxaban resulted in effective Factor Xa and TG inhibition, and was well-tolerated. Studies are needed to confirm edoxaban (60 mg daily) use in clinical practice. SPONSORSHIP Daiichi Sankyo Pharma Development.


Thrombosis Research | 2012

Risk assessment models for thromboprophylaxis of medical patients.

Meyer Michel Samama; Sophie Combe; Jacqueline Conard; Marie-Hélène Horellou

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 What is a risk factor and how to classify? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Quantification of Risk in a Multifactorial Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 RAMs Objectives and Process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Development of RAMs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 RAMs in the literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Non-validated RAMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 Validated RAMs in the literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 Non electronic alerts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130 RAMs in medical outpatients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131


Thrombosis Research | 2003

In vitro effect of melagatran and lepirudin on clot-bound thrombin

Jamal Lebrazi; Ismail Elalamy; Meyer Michel Samama

Thrombin converts fibrinogen into fibrin monomers by cleaving fibrinopeptides A and B from aminoterminal regions of Aa and Bh chains of fibrinogen, respectively [1]. During this reaction, thrombin is adsorbed to fibrin through the fibrin(ogen)-binding site located within the E domain [2,3]. The fibrin-bound thrombin retains its enzymatic activity and has the potential to induce thrombosis extension [4]. Given this central role of thrombin, most treatment strategies for acute coronary syndromes are aimed at inhibiting its generation or blocking its activity [5–7]. In vitro studies have shown that fibrin-bound thrombin is relatively protected from inactivation by heparin-antithrombin and this inactivation requires ligation of both exosites 1 and 2 of thrombin [8,9]. These findings could explain why heparin is limited in its ability to inhibit the extension of venous thrombosis and to prevent rethrombosis after successful thrombolysis [3]. Thus, direct thrombin inhibitors may represent alternatives to the treatment with heparin. At present, most clinical benefits of recombinant (r)hirudin have been demonstrated in the management of patients with heparin-induced thrombocytopenia. For this reason, lepirudin (a form of r-hirudin) has recently been approved for anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease [10,11].


Thrombosis Research | 2007

Screening for aspirin resistance in stable coronary artery patients by three different tests

Tahar Chakroun; Faouzi Addad; Fatma Abderazek; Mohamed Ben-Farhat; Sonia Hamdi; Habib Gamra; Mohsen Hassine; Khaldoun Ben-Hamda; Meyer Michel Samama; Ismail Elalamy


Journal of Thrombosis and Thrombolysis | 2010

Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease

Faouzi Addad; Tahar Chakroun; Fatma Abderazek; Mohamed Ben-Farhat; Sonia Hamdi; Zohra Dridi; Habib Gamra; Mohsen Hassine; Meyer Michel Samama; Ismail Elalamy


Archive | 2008

Measuring rivaroxaban pharmacodynamics: prothrombinase-induced clotting time (PiCT ® ) and Heptest ®

Meyer Michel Samama; Léna Le Flem; Céline Guinet; Elisabeth Perzborn; François Depasse


Archive | 2009

Suitability of Chromogenic Anti-Factor Xa Methods to Measure Rivaroxaban in Human Plasma

Meyer Michel Samama; Léna Le Flem; Céline Guinet; Elisabeth Perzborn; Jean Amiral; François Depasse


Archive | 2008

Effects of rivaroxaban and fondaparinux on clotting assays

Meyer Michel Samama; Léna Le Flem; Céline Guinet; Elisabeth Perzborn; Jean-Luc Martinoli; François Depasse


Archive | 2012

Anti-Factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicentre field trial

Meyer Michel Samama; Genevieve Contant; Theodore E. Spiro; Elisabeth Perzborn; Céline Guinet; Yves Gourmelin; Léna Le Flem; Gabriele Rohde; Jean Luc Martinoli


Archive | 2012

Prothrombin time assay for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicentre field trial

Meyer Michel Samama; Genevieve Contant; Theodore E. Spiro; Elisabeth Perzborn; Léna Le Flem; Céline Guinet; Yves Gourmelin; Jean Luc Martinoli

Collaboration


Dive into the Meyer Michel Samama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elisabeth Perzborn

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Habib Gamra

University of Southern California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Theodore E. Spiro

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge